Companies › A2 Biotherapeutics
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| A2B530 Logic-gated CAR T-cell targeting CEA; selective activation in HLA-A*02 negative cells | CEACAM5 | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| A2B543 Mesothelin-targeting logic-gated CAR T cell therapy | MSLN | Phase 1 | Solid Tumor, Adult | Jun 2028 |
| A2B694 Mesothelin-targeting logic-gated CAR T cell therapy | MSLN | Phase 1 | Solid Tumor, Adult | Jun 2028 |
| A2B395 Allogeneic logic-gated CAR T cells targeting EGFR with HLA-A*02 loss as kill-switch | EGFR | Phase 1 | Solid Tumor, Adult | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05736731 | A2B530 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT06051695 | A2B694 | Phase 1 | Solid Tumor, Adult | Oncology | Jun 2028 |
| NCT06051695 | A2B543 | Phase 1 | Solid Tumor, Adult | Oncology | Jun 2028 |
| NCT06682793 | A2B395 | Phase 1 | Solid Tumor, Adult | Oncology | Mar 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.